These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 29051184

  • 1. Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia.
    Opoka RO, Ndugwa CM, Latham TS, Lane A, Hume HA, Kasirye P, Hodges JS, Ware RE, John CC.
    Blood; 2017 Dec 14; 130(24):2585-2593. PubMed ID: 29051184
    [Abstract] [Full Text] [Related]

  • 2. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC, Opoka RO, Latham TS, Hume HA, Nabaggala C, Kasirye P, Ndugwa CM, Lane A, Ware RE.
    N Engl J Med; 2020 Jun 25; 382(26):2524-2533. PubMed ID: 32579813
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B, Lane A, Smart LR, Santos B, Tshilolo L, Williams TN, Olupot-Olupot P, Stuber SE, Tomlinson G, Latham T, Ware RE, REACH Investigators.
    Lancet Haematol; 2024 Jun 25; 11(6):e425-e435. PubMed ID: 38701812
    [Abstract] [Full Text] [Related]

  • 5. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Olupot P, Lane A, Aygun B, Stuber SE, Latham TS, McGann PT, Ware RE, REACH Investigators.
    N Engl J Med; 2019 Jan 10; 380(2):121-131. PubMed ID: 30501550
    [Abstract] [Full Text] [Related]

  • 6. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N, Eckman J, Varma M, Ramirez G, Adler B, Smith W, Carlos T, Ataga K, DeCastro L, Bigelow C, Saunthararajah Y, Telfer M, Vichinsky E, Claster S, Shurin S, Bridges K, Waclawiw M, Bonds D, Terrin M.
    JAMA; 2003 Apr 02; 289(13):1645-51. PubMed ID: 12672732
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 02; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 8. Realizing effectiveness across continents with hydroxyurea: Enrollment and baseline characteristics of the multicenter REACH study in Sub-Saharan Africa.
    McGann PT, Williams TN, Olupot-Olupot P, Tomlinson GA, Lane A, Luís Reis da Fonseca J, Kitenge R, Mochamah G, Wabwire H, Stuber S, Howard TA, McElhinney K, Aygun B, Latham T, Santos B, Tshilolo L, Ware RE, REACH Investigators.
    Am J Hematol; 2018 Aug 02; 93(4):537-545. PubMed ID: 29318647
    [Abstract] [Full Text] [Related]

  • 9. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC, Ware RE, Miller ST, Iyer RV, Casella JF, Minniti CP, Rana S, Thornburg CD, Rogers ZR, Kalpatthi RV, Barredo JC, Brown RC, Sarnaik SA, Howard TH, Wynn LW, Kutlar A, Armstrong FD, Files BA, Goldsmith JC, Waclawiw MA, Huang X, Thompson BW, BABY HUG investigators.
    Lancet; 2011 May 14; 377(9778):1663-72. PubMed ID: 21571150
    [Abstract] [Full Text] [Related]

  • 10. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH, Smeltzer MP, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS.
    Am J Hematol; 2017 Dec 14; 92(12):1333-1339. PubMed ID: 28913922
    [Abstract] [Full Text] [Related]

  • 11. Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub-Saharan Africa: Rationale and Design of the REACH Trial.
    McGann PT, Tshilolo L, Santos B, Tomlinson GA, Stuber S, Latham T, Aygun B, Obaro SK, Olupot-Olupot P, Williams TN, Odame I, Ware RE, REACH Investigators.
    Pediatr Blood Cancer; 2016 Jan 14; 63(1):98-104. PubMed ID: 26275071
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O, Yovetich NA, Scott JP, Owen W, Miller ST, Schultz W, Lockhart A, Aygun B, Flanagan J, Bonner M, Mueller BU, Ware RE, Investigators of the Stroke With Transfusions Changing to Hydroxyurea Clinical Trial (SWiTCH).
    Am J Hematol; 2013 Nov 14; 88(11):932-8. PubMed ID: 23861242
    [Abstract] [Full Text] [Related]

  • 14. Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa.
    Olupot-Olupot P, Tomlinson G, Williams TN, Tshilolo L, Santos B, Smart LR, McElhinney K, Howard TA, Aygun B, Stuber SE, Lane A, Latham TS, Ware RE.
    Blood; 2023 Mar 23; 141(12):1402-1410. PubMed ID: 36375125
    [Abstract] [Full Text] [Related]

  • 15. Hydroxyurea reduces infections in children with sickle cell anemia in Uganda.
    Namazzi R, Bond C, Conroy AL, Datta D, Tagoola A, Goings MJ, Jang JH, Ware RE, Opoka R, John CC.
    Blood; 2024 Apr 04; 143(14):1425-1428. PubMed ID: 38169476
    [Abstract] [Full Text] [Related]

  • 16. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.
    Pediatr Hematol Oncol; 1999 Apr 04; 16(3):221-32. PubMed ID: 10326220
    [Abstract] [Full Text] [Related]

  • 17. Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial.
    Power-Hays A, Tomlinson GA, Tshilolo L, Santos B, Williams TN, Olupot-Olupot P, Smart LR, Aygun B, Lane A, Stuber SE, Latham T, Ware RE.
    Am J Hematol; 2024 Apr 04; 99(4):625-632. PubMed ID: 38332651
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Magnesium for treating sickle cell disease.
    Than NN, Soe HHK, Palaniappan SK, Abas AB, De Franceschi L.
    Cochrane Database Syst Rev; 2019 Sep 09; 9(9):CD011358. PubMed ID: 31498421
    [Abstract] [Full Text] [Related]

  • 20. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL, Sarathi V, Desai S, Bhatnagar M, Lodha A.
    Hemoglobin; 2012 Sep 09; 36(4):323-32. PubMed ID: 22734586
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.